Literature DB >> 3689122

The impact of delayed surgery on radiotherapy dose and local control of rhabdomyosarcoma.

E Etcubanas1, B N Rao, L E Kun, M E Horowitz, D M Parham, H O Hustu, A A Green.   

Abstract

To determine if delayed surgery permits the modification of radiotherapy dose while maintaining local control in children with localized, unresectable rhabdomyosarcoma, a prospective study was launched in 1981 to test this objective. Treatment consisted of 16 weeks of preoperative chemotherapy, with or without delayed surgery, and radiotherapy using 35 to 40 Gy (3500 to 4000 rad) for microscopic and 50 to 55 Gy (5000 to 5500 rad) for gross residual tumor, plus 14 months of chemotherapy. Among 22 patients treated, surgery was feasible in 11 of 14 patients with residual tumor after chemotherapy and was performed in eight (avoiding radical surgery in three), leaving microscopic (seven patients) or gross residual (one patient) tumor. Progressive disease or amputation precluded radiotherapy in two patients. After radiotherapy local control was sustained in 12 of 14 patients with microscopic lesions vs none of six patients with gross tumor. Delayed surgery may permit the use of lower-dose radiotherapy and should be considered in the treatment plan for this subset of patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689122     DOI: 10.1001/archsurg.1987.01400240099018

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  David O Walterhouse; Alberto S Pappo; Jane L Meza; John C Breneman; Andrea A Hayes-Jordan; David M Parham; Timothy P Cripe; James R Anderson; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

2.  Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.

Authors:  John Breneman; Jane Meza; Sarah S Donaldson; R Beverly Raney; Suzanne Wolden; Jeff Michalski; Fran Laurie; David A Rodeberg; William Meyer; David Walterhouse; Douglas S Hawkins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-19       Impact factor: 7.038

3.  Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  R Beverly Raney; David O Walterhouse; Jane L Meza; Richard J Andrassy; John C Breneman; William M Crist; Harold M Maurer; William H Meyer; David M Parham; James R Anderson
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

4.  Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Authors:  David A Rodeberg; Moody D Wharam; Elizabeth R Lyden; Julie A Stoner; Kenneth Brown; Suzanne L Wolden; Charles N Paidas; Sarah S Donaldson; Douglas S Hawkins; Sheri L Spunt; Carola A Arndt
Journal:  Int J Cancer       Date:  2014-12-10       Impact factor: 7.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.